Atossa nears regulatory resolution for cancer Dx; German firm found liable in breast implant scandal;

@FierceMedDev: TriVascular lands $40M round for aortic stent grafts. Story | Follow @FierceMedDev

@MarkHFierce: Medtronic's latest earnings report comes out on Nov. 19. | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Brain tumors succumb to drugs delivered via bone scaffold. More | Follow @MichaelGFierce

> A court recently found the German safety standards firm TUV Rheinland liable in a global scandal over substandard breast implants made by the now-defunct French firm PIP. Story

> Atossa Genetics ($ATOS) said it had a fruitful pre-510(k) submission meeting with the FDA regarding its ForeCYTE Breast Pump and patient kit, potentially overcoming a warning letter that chided the company for marketing the now-recalled cancer diagnostic device without agency clearance. Item

> Corgenix has sealed a collaborative diagnostic test development deal with Zalgen Labs. Item

> A South Carolina startup envisions using magnets to lock and unlock a knee replacement system to help patients have more mobility. Story

> FBC Device gained a CE mark for its new spinal fusion plant and will launch the device in Europe and Canada. Item

Biotech News

@FierceBiotech: Tufts: Big Pharma bets its future on a swelling pipeline of biologic. Article | Follow @FierceBiotech

@JohnCFierce: AbbVie scores SVRs of 95% and 98% for GT1a and GT1b groups in first PhIII hep C study. More | Follow @JohnCFierce

@DamianFierce: FierceBiotech, coming soon to an Android near you. (Get your iPhone/iPad version in the iTunes store.) Download | Follow @DamianFierce

@EmilyMFierce: Federal government to transfer laboratory chimps to sanctuaries. Story | Follow @EmilyMFierce

> Big Pharma venture teams back Aileron's shift to early-stage R&D. Article

> Pfizer joins Roche, GSK in $32M round for Mission Therapeutics. More

> In another big cancer setback, Sanofi shutters fedratinib program. News

Pharma News

@FiercePharma: The weekend's best-read special report: Top Pharma Companies by 2012 Revenues. Read | Follow @FiercePharma

@EricPFierce: Pfizer gives BlackBerry the raspberry. Piece | Follow @EricPFierce

@CarlyHFierce: Tufts University report: 71% of revenue from the top 10 best-selling meds last year came from #biotech products. Report | Follow @CarlyHFierce

> GlaxoSmithKline CEO: Big Pharma has to be willing to concede in India. News

> Princeton weighs emergency vaccine campaign with Novartis' Bexsero shot. More

> Takeda's new outsider CFO charged with $1B cost-cutting plan. Article

CRO News

> Post-merger PRA makes another buy, grabbing CRI Lifetree. More

> WuXi boosts outlook as Chinese CRO market swells. Story

> Icon rolls out data visualization tech for adaptive trials. News

> Quintiles expands trial monitoring to slash study costs. Article

> Report: Medpace up for $1.2B sale as CRO M&A heats up. Report

> Catalent cuts ribbon on Chinese trial-supply facility. Item

Biotech IT News

> Falling cost of next-gen sequencing to drive informatics boom. News

> Pfizer takes steps to protect itself from BlackBerry's woes. More

> Validic raises cash to turn mHealth app output into data hose. Piece

> Pfizer finally takes control of Twitter account. Item

> EMA warns of possible delay to final trial data transparency policy. Article